A multicenter, open, single sequence crossover study to assess the safety and efficacy of a tacrolimus modified release, FK506E (MR4), based immunosuppressive regimen in stable liver transplant patients converted from a Prograf [tacrolimus] based immunosuppressive regimen
Phase of Trial: Phase III
Latest Information Update: 28 Jun 2012
At a glance
- Drugs Tacrolimus (Primary)
- Indications Liver transplant rejection
- Focus Adverse reactions; Registrational
- Sponsors Astellas Pharma
- 28 Jun 2012 Planned number of patients changed from 106 to 125 as reported by European Clinical Trials Database.
- 18 Feb 2009 Actual patient numbers (112) added as reported by ClinicalTrials.gov.
- 07 May 2008 New trial record.